Dual β-lactam for treatment of pulmonary <i>Mycobacterium abscessus</i> in a child
Bradford Becken, Khalid M Dousa, John L. Johnson, Steven M. Holland, Robert A. Bonomo
Antimicrobial Agents and Chemotherapy · 2024-05
Abstract
ABSTRACT Treatment of Mycobacterium abscessus infection presents significant challenges, exacerbated by the emergence of macrolide-resistant strains that necessitate the use of multiple antimicrobials in combination and carry the potential for significant toxic effects. Select dual beta-lactam combinations, with or without beta-lactamase inhibitors, have been shown to be highly active in vitro . Herein, we describe a 6-year-old child with underlying mild bilateral lower lobe cylindrical bronchiectatic lung disease who developed pulmonary Mycobacterium abscessus infection and was treated with a multi-drug regimen including two β-lactam antibiotics, achieving both early clinical and microbiological cure. This case highlights the potential benefit of dual β-lactam therapy for the treatment of drug-resistant Mycobacterium abscessus infection.
MeSH terms
- Mycobacterium abscessus
- Antibiotics
- Medicine
- Bronchiectasis
- Antimicrobial
- Microbiology
- Drug resistance
- Lung
- Nontuberculous mycobacteria
- Regimen
- Mycobacterium
- Beta-lactam
- Mycobacterium avium complex
- Immunology